Employees: 21
Size Immix Biopharma (IMMX) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $596M, the 2556th largest of 3,085 United States companies the cockpit tracks. Shares closed at $7.11 on 18 Nov 2026.
Performance Over six months the shares fell 20.5%, against -31.3% for the median peer and -2.2% for the United States market (cap-weighted) — 7th highest of 20 in its peer set.
Next results Next results expected around 3 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Revenue growth | — | — | — | — | — |
| Gross profit | -$467,861 | -$364,501 | -$115,388 | -$5,468 | -$2,135 |
| EBITDA | -$49.5M | -$26.8M | -$22.5M | -$16.1M | -$8.22M |
| Net income | -$46.3M | -$29.4M | -$21.6M | -$15.4M | -$8.23M |
| Free cash flow | -$45.2M | -$24.7M | -$15.8M | -$11.4M | -$7.41M |
| Capital expenditure | $339,896 | $732,925 | $1.18M | $52,089 | $0 |
| Total debt | $965,053 | $1.07M | $1.07M | $0 | $0 |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | IMMX | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -20.2% | -11.5% | 3rd lowest of 20 |
| 6-month return | -20.5% | -31.3% | 7th highest of 20 |
| Distance from 52-week high | -52.9% | -43.9% | 8th lowest of 20 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Immix Biopharma IMMX | United States | $596M | -20% | n/a | n/a | n/a | n/a | n/a |
| JIANMIN PHARMACEUTICAL 600976.SS | China | $598M | -14% | -2% | 8% | 0.9× | -6.2% | +6.5% |
| Xiangxue Pharmaceutical 300147.SZ | China | $591M | -41% | +3% | -39% | 3.7× | 50.4% | -12.3% |
| Hangzhou Bio-Sincerity Pharma-Tech 301096.SZ | China | $602M | -38% | +5% | -30% | 7.5× | n/a | n/a |
| Shandong Jincheng Pharmaceutical 300233.SZ | China | $604M | -31% | +2% | 4% | 1.2× | -0.6% | -1.6% |
| DBV Technologies DBV.PA | France | $604M | -46% | n/a | n/a | n/a | n/a | n/a |
| Cullinan Therapeutics CGEM | United States | $585M | -37% | n/a | n/a | n/a | n/a | n/a |
| GuiZhou SanLi Pharmaceutical 603439.SS | China | $583M | -20% | -6% | 5% | 2.6× | 20.9% | +21.9% |
| Chongkundang 185750.KS | South Korea | $609M | -27% | +6% | 4% | 0.5× | -6.6% | +5.4% |
| Luoxin Pharmaceuticals Group Stock 002793.SZ | China | $609M | -26% | -10% | -9% | 2.0× | -1.0% | -17.9% |
| Achieve Life Sciences QUIT | United States | $609M | n/a | n/a | n/a | n/a | n/a | n/a |
| HeiLongJiang ZBD Pharmaceutical 603567.SS | China | $610M | -39% | -82% | n/a | 25.1× | 9.1% | -25.1% |
| Zhejiang Anglikang Pharmaceutical 002940.SZ | China | $612M | -52% | -13% | 10% | 3.3× | 10.1% | +2.1% |
| Fuan Pharmaceutical (Group) 300194.SZ | China | $612M | -14% | -3% | -1% | 2.4× | 10.9% | -5.9% |
| Lepu Biopharma 2157.HK | Hong Kong | $580M | -43% | +47% | 7% | 4.5× | n/a | n/a |
| Oneness Biotech 4743.TWO | Taiwan | $580M | -13% | +19% | -589% | 101.5× | n/a | n/a |
| Orchid Pharma ORCHPHARMA.NS | India | $613M | +30% | +11% | 0% | 6.1× | n/a | n/a |
| TTY Biopharm 4105.TWO | Taiwan | $615M | +10% | +5% | 29% | 3.0× | -8.7% | +8.8% |
| Abbisko Cayman 2256.HK | Hong Kong | $578M | -39% | -83% | -520% | 20.1× | n/a | n/a |
| Beijing Tong Ren Tang Chinese Medicine 3613.HK | Hong Kong | $577M | -26% | -21% | 32% | 1.9× | -15.4% | +2.8% |
| Olema Pharmaceuticals OLMA | United States | $619M | -49% | n/a | n/a | n/a | n/a | n/a |